Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-CKD: Empagliflozin for Sickle Cell-Related Kidney Disease
NCT07175051Phase 2Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Apr 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin in albuminuria, sponsored by University of Illinois Chicago. Primary endpoints: Urine biomarker: Adenosine at 48 weeks, Urine biomarker: Nephrin at 48 weeks and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
albuminuria
Beyond the preview
Go deeper on NCT07175051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07175051.